Menu

Professional Practice Guidelines

 

A number of medical specialty societies and expert groups have issued guidelines on hereditary cancer testing.  Myriad has formed its assessment criteria based on the following medical society guidelines.  A healthcare specialist may use assessment criteria based on that specialist's medical society guidelines, or based on his/her own professional judgment, which may differ from Myriad's assessment guidelines. 

BRACAnalysis® Testing for
Hereditary Breast and Ovarian Cancer (HBOC)

NCCN - National Comprehensive Cancer Network (login required)

 - American Congress of Obstetricians and Gynecologists

 - American Society of Breast Surgeons (pdf)

ASCO® - American Society of Clinical Oncology

 - Society of Gynecologic Oncology

USPSTF - U.S. Preventive Services Task Force

There may be additional professional practice guidelines for HBOC testing than those listed above that a healthcare specialist may want to consider, including the following:

 - Association of Community Cancer Centers

AMA - American Medical Association

NSGC - National Society of Genetic Counselors

ONS - Oncology Nursing Society

 - Society of Gynecologic Oncology

Society of Surgical Oncology logo - Society of Surgical Oncology

COLARIS® and COLARIS AP® Testing for
Lynch syndrome and Polyposis syndromes

 - Association of Community Cancer Centers

AMA - American Medical Association

ASCRS - American Society of Colon and Rectal Surgeons

AGA - American Gastroenterological Association

ASCO® - American Society of Clinical Oncology

NCCN - National Comprehensive Cancer Network

NSGC - National Society of Genetic Counselors

ONS - Oncology Nursing Society

Society of Surgical Oncology logo - Society of Surgical Oncology

 

BRACAnalysis, COLARIS, COLARIS AP, MELARIS, Myriad myPath, myPlan, myRisk, TheraGuide, PREZEON, PANEXIA, and Prolaris are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions